Cytori Projections to 2020 edited 5-19-16
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABNOPQRSUVWXYZAAABACADAEAFAGAH
1
Income Sources
2015 A2016 E2017 E2018 E2019 E2020 EPatients treated in formulas
2
Japan $ 2,394,000 $ 3,591,000 $ 5,386,500 $ 13,642,250 $ 38,869,625 $ 79,304,438 201820192020
3
general therapies (aesthetics, OA, IBD)
$ 2,394,000 $ 3,591,000 $ 5,386,500 $ 8,079,750 $ 12,119,625 $ 18,179,438 N/AN/AN/A
4
Urinary Incontinence $ - $ - $ - $ 1,562,500 $ 8,750,000 $ 13,125,000 63350525
5
Scleroderma $ - $ - $ - $ 4,000,000 $ 18,000,000 $ 48,000,000 1004501200
6
Asia Pacific - Lorem (all therapies)
$ 787,000 $ - $ - $ - $ - $ -
7
Europe $ 675,000 $ 2,675,000 $ 26,180,000 $ 49,380,000 $ 103,480,000 $ 156,640,000
8
general therapies (aesthetics, OA, IBD)
$ 595,000 $ 625,000 $ 1,050,000 $ 1,500,000 $ 2,250,000 $ 3,000,000 5007501,000
9
scleroderma (net of Idis partner) $ 80,000 $ 2,000,000 $ 25,000,000 $ 10,000,000 $ - $ - 20000
10
scleroderma - Approval (net of partner)
$ - $ - $ - $ 37,500,000 $ 100,000,000 $ 150,000,000 15004,0006,000
11
Bimini (Puregraft Royalties + Alopecia)
$ - $ 50,000 $ 130,000 $ 380,000 $ 1,230,000 $ 3,640,000 3001,0003,000
12
Americas $ 982,000 $ 1,137,000 $ 1,536,000 $ 24,605,000 $ 243,274,000 $ 349,828,000
13
general therapies (aesthetics, OA, IBD)
$ 35,000 $ 75,000 $ 100,000 $ 125,000 $ 150,000 $ 20,000,000 N/AN/A10,000
14
Okyanos/ Thorn Medical $ 900,000 $ 1,000,000 $ 1,200,000 $ 1,400,000 $ 1,600,000 $ 1,800,000 350400450
15
Celase GMP (Worthington Biochemical)
$ 5,000 $ 12,000 $ 16,000 $ 20,000 $ 24,000 $ 28,000 N/AN/AN/A
16
Bimini (Puregraft Royalties + Alopecia)
$ 42,000 $ 50,000 $ 220,000 $ 560,000 $ 1,500,000 $ 4,000,000 3001,0003,000
17
Scleroderma $ - $ - $ - $ 22,500,000 $ 225,000,000 $ 300,000,000 5182,8804,500
18
Thermal burns (BARDA Purchase in 2019)
$ - $ - $ - $ - $ 15,000,000 $ 24,000,000 006,000
19
Product Revenues
$ 4,838,000 $ 7,403,000 $ 33,102,500 $ 87,627,250 $ 385,623,625 $ 585,772,438
20
Cost of Product Revenues
$ 3,186,000 $ 3,331,350 $ 11,585,875 $ 21,906,813 $ 57,843,544 $ 87,865,866
21
Gross Profit $ 1,652,000 $ 4,071,650 $ 21,516,625 $ 65,720,438 $ 327,780,081 $ 497,906,572
22
34.1%55.0%65.0%75.0%85.0%85.0%
23
Development Revenues:
27
Government BARDA Contract and other
$ 6,821,000 $ 6,900,000 $ 6,900,000 $ 6,900,000 $ 6,900,000 $ 6,900,000
28
Total Development Revenues $ 6,821,000 $ 6,900,000 $ 6,900,000 $ 6,900,000 $ 6,900,000 $ 6,900,000
29
Total Revenue $ 11,659,000 $ 14,303,000 $ 40,002,500 $ 94,527,250 $ 392,523,625 $ 592,672,438
30
Operating Expenses:
31
Research and Development $ 19,000,000 $ 16,100,000 $ 10,417,000 $ 10,417,000 $ 14,417,000 $ 15,417,000
32
Sales and Marketing $ 2,662,000 $ 2,750,000 $ 3,400,000 $ 10,000,000 $ 15,000,000 $ 20,000,000
33
General and Administrative $ 9,765,000 $ 9,800,000 $ 10,300,000 $ 15,000,000 $ 20,000,000 $ 25,000,000
37
Total Operating Expenses $ 23,759,000 $ 28,650,000 $ 24,117,000 $ 35,417,000 $ 49,417,000 $ 60,417,000
38
Operating Gain (Loss) $ (15,286,000) $ (17,678,350) $ 4,299,625 $ 37,203,438 $ 285,263,081 $ 444,389,572
39
Other Income (expense):
43
Interest Income $ 9,000 $ 5,000 $ 2,000 $ 10,000 $ 378,151 $ 3,230,963
44
Interest Expense $ (3,379,000) $ (2,655,000) $ (2,200,000) $ (1,300,000) $ (260,000) $ -
45
Other Income (Expense), net $ (88,000) $ (100,000) $ (100,000) $ (100,000) $ (100,000) $ (100,000)
48
Total Other Income (Expense) $ (3,458,000) $ (2,750,000) $ (2,298,000) $ (1,390,000) $ 18,151 $ 3,130,963
49
Net Gain (Loss) $ (19,405,000) $ (20,428,350) $ 2,001,625 $ 35,813,438 $ 285,281,232 $ 447,520,535
50
Foreign Currency Translation Adjustments
$ 296,000 $ 400,000
52
Net Comprehensive Gain (Loss)
$ (19,109,000) $ (20,028,350) $ 2,001,625 $ 35,813,438 $ 285,281,232 $ 447,520,535
53
Income Taxes
$ - $ - $ - $ - $ - $ -
54
Net Income After Tax
$ (19,109,000) $ (20,028,350) $ 2,001,625 $ 35,813,438 $ 285,281,232 $ 447,520,535
55
56
Diluted Net Loss per Common Share
$ (2.04) $ (0.96) $ 0.09 $ 1.64 $ 12.79 $ 19.62
57
Diluted Weighted Average Common Shares
9,386,488 20,810,740 21,310,740 21,810,740 22,310,740 22,810,740
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
Loading...
Main menu